<?xml version='1.0' encoding='utf-8'?>
<document id="18651556"><sentence text="Marked impact of P-glycoprotein on the absorption of TAK-427 in rats."><entity charOffset="53-60" id="DDI-PubMed.18651556.s1.e0" text="TAK-427" /></sentence><sentence text="The role of P-glycoprotein (P-gp, ABCB1) on the absorption process was investigated by drug-drug interaction studies of TAK-427 with P-gp inhibitors (erythromycin, ketoconazole or quinidine) in rats and by transport studies using rat multidrug resistance (MDR1) stably expressing cells and rat small intestine mounted in a Ussing-type chamber"><entity charOffset="150-162" id="DDI-PubMed.18651556.s2.e0" text="erythromycin" /><entity charOffset="164-176" id="DDI-PubMed.18651556.s2.e1" text="ketoconazole" /><entity charOffset="180-189" id="DDI-PubMed.18651556.s2.e2" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.18651556.s2.e0" e2="DDI-PubMed.18651556.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18651556.s2.e0" e2="DDI-PubMed.18651556.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18651556.s2.e0" e2="DDI-PubMed.18651556.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18651556.s2.e1" e2="DDI-PubMed.18651556.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18651556.s2.e1" e2="DDI-PubMed.18651556.s2.e2" /></sentence><sentence text=" TAK-427 showed high efflux activity with low permeability in rat MDR1a and MDR1b stably expressing cells and was revealed to be a typical substrate for P-gps" /><sentence text=" Although TAK-427 was mainly absorbed from the small intestine in rats, a large part of the dosed compound remained in the gastrointestinal tract"><entity charOffset="10-17" id="DDI-PubMed.18651556.s4.e0" text="TAK-427" /></sentence><sentence text=" Orally co-administered P-gp inhibitors (50 mg/kg) increased the AUC of TAK-427 after a 5 mg/kg oral dose 5" /><sentence text="4- to 18" /><sentence text="3-fold, whereas orally administered P-gp inhibitors had a minor effect on the increase in the AUC of TAK-427 (1" /><sentence text="3- to 2" /><sentence text="2-fold) after a 0" /><sentence text="5 mg/kg intravenous dose" /><sentence text=" Thus, the bioavailability of TAK-427 after oral administration in rats (7"><entity charOffset="30-37" id="DDI-PubMed.18651556.s11.e0" text="TAK-427" /></sentence><sentence text="3%) markedly increased when co-administered with P-gp inhibitors (28" /><sentence text="6-57" /><sentence text="6%)" /><sentence text=" Moreover, the transport of TAK-427 was predominantly secretory throughout the rat small intestine and was inhibited by P-gp inhibitors" /><sentence text=" In conclusion, P-gp can markedly reduce the absorption of a typical P-gp substrate by its efflux activity throughout the absorption site" /><sentence text="" /></document>